Abstract
As the landscape for hidradenitis suppurativa (HS) medical treatment is rapidly expanding, seemingly taking the same steps that marked the evolution of psoriasis management, upcoming agents still do not appear to offer complete disease control. Better control of severe cases of HS refractory to biologic monotherapy may require investigation of pathogenesis-driven, combination regimens sooner rather than later.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
